Overview Financials News + Filings Key Docs Charts Ownership Insiders |
AGILE THERAPEUTICS INC (AGRX)
|
Add to portfolio |
|
|
Price: |
$1.87
| | Metrics |
OS: |
1.93
|
M
| |
|
|
Market cap: |
$3.6
|
M
| |
|
|
Net cash:
|
$2.28
|
M
| |
$1.19
|
per share
|
EV:
|
$1.32
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($36.9)
|
M
| |
|
|
EBIT
|
($37.4)
|
M
| |
|
|
EPS |
($7.75)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 10.9 | 4.1 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Revenue growth | 165.4% | 447.5% | | | | | | |
Cost of goods sold | 6.8 | 10.7 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross profit | 4.0 | -6.6 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross margin | 37.2% | -161.4% | 62.3% | | | | | |
Sales and marketing | 30.4 | 43.4 | 23.3 | 1.1 | 0.9 | | | |
Research and development | 3.3 | 6.2 | 13.5 | 9.9 | 9.8 | 14.4 | 20.9 | 25.6 |
General and administrative | 11.9 | 14.7 | 12.7 | 7.9 | 7.8 | 12.4 | 8.8 | 7.5 |
EBITA | -52.3 | -70.8 | -48.9 | -18.7 | -18.5 | -26.8 | -29.7 | -33.1 |
EBITA margin | -480.5% | -1727.5% | -6526.3% | | | | | |
Amortization of intangibles | 0.3 | 0.2 | 0.2 | 0.1 | | | | |
EBIT | -52.6 | -71.0 | -49.1 | -18.9 | -18.5 | -26.8 | -29.7 | -33.1 |
EBIT margin | -482.9% | -1731.4% | -6549.1% | | | | | |
Pre-tax income | -30.1 | -71.1 | -51.9 | -18.6 | -20.3 | -28.3 | -31.8 | -36.3 |
Income taxes | -4.7 | 0.0 | 0.0 | 0.0 | -0.5 | 0.0 | -3.1 | -6.0 |
Tax rate | 15.5% | 0.0% | 0.0% | 0.0% | 2.4% | 0.0% | 9.7% | 16.4% |
Net income | -25.4 | -71.1 | -51.9 | -18.6 | -19.8 | -28.3 | -28.7 | -30.3 |
Net margin | -233.5% | -1732.9% | -6923.0% | | | | | |
|
Diluted EPS | ($1.18) | ($29.28) | ($24.49) | ($0.38) | ($0.58) | ($0.91) | ($1.02) | ($1.38) |
Shares outstanding (diluted) | 21.6 | 2.4 | 2.1 | 49.4 | 34.3 | 30.9 | 28.3 | 22.0 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|